Evidence map›Paper›PMID 33335282›Full record

ReviewNature reviews. Gastroenterology & hepatology2021

Human biomimetic liver microphysiology systems in drug development and precision medicine.

Albert Gough, Alejandro Soto-Gutierrez, Lawrence Vernetti, Mo R Ebrahimkhani, Andrew M Stern, D Lansing Taylor

Abstract readReview
In one paragraph

Review in Nature reviews. Gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Biomimetic Vascularized iPSC-Hepatocyte Spheroids for Liver Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Albert GoughUniversity of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-6456-0195
Alejandro Soto-GutierrezUniversity of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Lawrence VernettiUniversity of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-4861-3167
Mo R EbrahimkhaniDepartment of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
Andrew M SternUniversity of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, USA.
D Lansing TaylorUniversity of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA, USA. dltaylor@pitt.edu.ORCID http://orcid.org/0000-0001-6947-1343

Funding

Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanomaU01TR002383 · NCATS · VANDERBILT UNIVERSITY · PI MURPHY, WILLIAM L., TAYLOR, D. LANSING · 2018 to 2022
$7.6M
Applying a Human Liver Microphysiology System to Develop Therapeutic Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)R01DK117881 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAYLOR, D. LANSING · 2018 to 2021
$2.7M
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver diseaseUG3TR003289 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BEHARI, JAIDEEP, SOTO-GUTIERREZ, ALEJANDRO · 2020 to 2021
$1.5M
NCATS NIH HHS U01 TR002383NCATS NIH HHS UG3 TR003289NIDDK NIH HHS R01 DK117881
6 · The paper itself

Abstract

Microphysiology systems (MPS), also called organs-on-chips and tissue chips, are miniaturized functional units of organs constructed with multiple cell types under a variety of physical and biochemical environmental cues that complement animal models as part of a new paradigm of drug discovery and development. Biomimetic human liver MPS have evolved from simpler 2D cell models, spheroids and organoids to address the increasing need to understand patient-specific mechanisms of complex and rare diseases, the response to therapeutic treatments, and the absorption, distribution, metabolism, excretion and toxicity of potential therapeutics. The parallel development and application of transdisciplinary technologies, including microfluidic devices, bioprinting, engineered matrix materials, defined physiological and pathophysiological media, patient-derived primary cells, and pluripotent stem cells as well as synthetic biology to engineer cell genes and functions, have created the potential to produce patient-specific, biomimetic MPS for detailed mechanistic studies. It is projected that success in the development and maturation of patient-derived MPS with known genotypes and fully matured adult phenotypes will lead to advanced applications in precision medicine. In this Review, we examine human biomimetic liver MPS that are designed to recapitulate the liver acinus structure and functions to enhance our knowledge of the mechanisms of disease progression and of the absorption, distribution, metabolism, excretion and toxicity of therapeutic candidates and drugs as well as to evaluate their mechanisms of action and their application in precision medicine and preclinical trials.

Indexed as

BiomimeticsDrug DevelopmentPrecision MedicineDrug Evaluation, PreclinicalHumansLab-On-A-Chip DevicesLiverMicrochip Analytical ProceduresMicrofluidicsModels, Animal

Identifiers

PMID33335282
PMCPMC9106093

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.